Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2026)

Vir Biotechnology has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $179.6 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $179.6 million, down 25.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $179.6 million (down 25.25% YoY), and the FY2025 annual result was $216.0 million, down 3.75% from the prior year.
• Total Non-Current Liabilities came in at $179.6 million for Q1 2026 at Vir Biotechnology, down from $216.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $867.2 million in Q1 2022 to a low of $179.6 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $240.3 million (2025), against an average of $377.6 million.
• Across the five-year window, Total Non-Current Liabilities jumped 101.81% in 2022 and sank 68.12% in 2024, its largest moves.
• Vir Biotechnology's Total Non-Current Liabilities stood at $699.2 million in 2022, then tumbled by 55.23% to $313.0 million in 2023, then decreased by 28.32% to $224.4 million in 2024, then fell by 3.75% to $216.0 million in 2025, then slipped by 16.84% to $179.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $179.6 million (Q1 2026), $216.0 million (Q4 2025), and $189.2 million (Q3 2025), per Business Quant data.